Relay Therapeutics is expected to report a second-quarter loss of $0.41 per share on revenue of $0.96 million, with the stock trading at $18.83 compared to an average analyst price target of $26.08.
Investors are primarily focused on clinical updates for zovegalisib (RLY-2608), the company's lead PI3Kα inhibitor currently being evaluated in the Phase 3 ReDiscover-2 trial for metastatic breast cancer.
With a reported cash balance of $642 million at the end of the first quarter, the company maintains a capital runway into 2029, allowing for aggressive pipeline expansion.
This quarter's highlights will likely center on recruitment timelines for breast cancer cohorts and progress in the NRAS-selective program.